Skip to main content

Table 2 Patient and SPL characteristics and outcomes of EUS-FNAB in UR SPL patients

From: Efficacy of EUS-guided FNB using a Franseen needle for tissue acquisition and microsatellite instability evaluation in unresectable pancreatic lesions

 

FNB, UR (N = 22)

FNA, UR (N = 36)

P value

Age, y, median (range)

68 (49–91)

70 (38–84)

0.79

Sex, male/female

15/7

21/15

0.58

Final diagnosis

  

0.52

 Pancreatic cancer

22

34

 

 Pancreatic neuroendocrine tumor

 

2

 

SPL size, mm, median (range)

30 (15–50)

30 (10–82)

0.70

SPL location, head/body or tail

8/14

14/22

1.0

Puncture route, gastric/duodenal

16/6

26/10

1.0

Puncture number, median (range)

3 (2–5)

4 (1–8)

0.036

Histological specimen, n (%)

22 (100)

26 (72.2)

< 0.01

Adverse events, n (%)

0 (0)

1 (2.8)

1.0

 Bleeding, n

 

1

 
  1. SPL Solid pancreatic lesion, UR unresectable